Apomorphine in the treatment of Parkinson's disease: a review

作者: Renata Ramina Pessoa , Adriana Moro , Renato Puppi Munhoz , Hélio A.G. Teive , Andrew J. Lees

DOI: 10.1590/0004-282X20180140

关键词:

摘要: Optimizing idiopathic Parkinson's disease treatment is a challenging, multifaceted and continuous process with direct impact on patients' quality of life. The basic tenet this task entails tailored therapy, allowing for optimal motor function the fewest adverse effects. Apomorphine, dopamine agonist used as rescue therapy patients fluctuations, potential positive effects nonmotor symptoms, only antiparkinsonian agent whose capacity to control symptoms comparable that levodopa. Subcutaneous administration, either an intermittent injection or infusion, appears be most effective tolerable route. This review summarizes historical background, structure, mechanism action, indications, contraindications side effects, compares apomorphine infusion other treatments, such oral deep brain stimulation enteral levodopa/carbidopa gel, gives practical instructions how initiate treatment.

参考文章(60)
Pablo Martinez-Martin, Prashanth Reddy, Angelo Antonini, Tove Henriksen, Regina Katzenschlager, Per Odin, Antonia Todorova, Yogini Naidu, Susanne Tluk, Chandni Chandiramani, Anne Martin, Kallol Ray Chaudhuri, Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson's disease compared to conventional therapy: a real life study of non motor effect. Journal of Parkinson's disease. ,vol. 1, pp. 197- 203 ,(2011) , 10.3233/JPD-2011-11037
Jose L Barboza, Michael S Okun, Baharak Moshiree, The treatment of gastroparesis, constipation and small intestinal bacterial overgrowth syndrome in patients with Parkinson's disease. Expert Opinion on Pharmacotherapy. ,vol. 16, pp. 2449- 2464 ,(2015) , 10.1517/14656566.2015.1086747
Rejko Krüger, Rüdiger Hilker, Christian Winkler, Michael Lorrain, Matthias Hahne, Christoph Redecker, Paul Lingor, Wolfgang H. Jost, Advanced stages of PD: interventional therapies and related patient-centered care Journal of Neural Transmission. ,vol. 123, pp. 31- 43 ,(2016) , 10.1007/S00702-015-1418-0
Per Odin, K Ray Chaudhuri, JT Slevin, Jens Volkmann, Espen Dietrichs, Pablo Martinez-Martin, JK Krauss, Tove Henriksen, R Katzenschlager, Angelo Antonini, Olivier Rascol, Werner Poewe, None, Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program. Parkinsonism & Related Disorders. ,vol. 21, pp. 1133- 1144 ,(2015) , 10.1016/J.PARKRELDIS.2015.07.020
Angelo Antonini, Ioannis U Isaias, Margherita Canesi, Maurizio Zibetti, Francesca Mancini, Luigi Manfredi, Marco Dal Fante, Leonardo Lopiano, Gianni Pezzoli, None, Duodenal levodopa infusion for advanced Parkinson's disease: 12‐month treatment outcome Movement Disorders. ,vol. 22, pp. 1145- 1149 ,(2007) , 10.1002/MDS.21500
Montse Alegret, Francesc Valldeoriola, MaJosé Martí, Manuela Pilleri, Carme Junqué, Jordi Rumià, Eduardo Tolosa, Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson's disease. Movement Disorders. ,vol. 19, pp. 1463- 1469 ,(2004) , 10.1002/MDS.20237
B. Kleedorfer, N. Turjanski, R. Ryan, A. J. Lees, C. Milroy, G. M. Stern, Intranasal apomorphine in Parkinson's disease Neurology. ,vol. 41, pp. 761- 762 ,(1991) , 10.1212/WNL.41.5.761-A
AndrewJ. Hughes, Sue Bishop, AndrewJ. Lees, GeraldM. Stern, Roy Webster, Michael Bovingdon, Rectal apomorphine in Parkinson's disease. The Lancet. ,vol. 337, pp. 118- ,(1991) , 10.1016/0140-6736(91)90780-S
John D O'Sullivan, Andrew J Lees, Use of apomorphine in Parkinson's disease Hospital Medicine. ,vol. 60, pp. 816- 820 ,(1999) , 10.12968/HOSP.1999.60.11.1236